KLOW peptide.

KLOW peptide: four ingredients in one blend

KLOW combines GHK-Cu, BPC-157, TB-500 and KPV. It adds KPV to the three ingredients in GLOW peptide. The supplied 80 mg vial contains 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV. Its ingredient ratio is 5:1:1:1 by mass. [1]

The ingredient balance matters more than the blend name. GHK-Cu makes up five eighths of every portion; each other ingredient makes up one eighth. Increasing the amount increases all four together. You cannot increase KPV alone or reduce GHK-Cu alone while using this fixed blend.

The blue colour comes from GHK-Cu. Its weight includes the peptide–copper complex, not just elemental copper. The product documents identify TB-500 as full-length, 43-amino-acid thymosin beta-4. That differs from the shorter fragment also sold under the TB-500 name. [2]

KLOW is a commercial combination name. It is not a single naturally occurring peptide, a GLP-1 medicine or a growth-hormone product. Its ingredients are studied for skin, inflammatory signaling and tissue repair; combining them does not automatically make every ingredient finding a proven effect of the finished blend.

KLOW, GLOW and Wolverine Stack

KPV is the specific difference between these GLOW and KLOW vials. It is a short peptide made from lysine, proline and valine. Its research focuses on inflammatory signaling, including intestinal and skin models. It does not supply an established human treatment dose for bowel disease or skin irritation. [3] [4]

A larger total is not necessarily more of every ingredient. A 4 mg KLOW portion contains the same GHK-Cu, BPC-157 and TB-500 amounts as 3.5 mg of this GLOW blend, plus 0.5 mg KPV. Comparing 4 mg of both blends would change the three shared ingredient amounts too.

No head-to-head human trial establishes that KLOW produces better skin or recovery results than GLOW or Wolverine Stack. The clear difference is composition. Match the extra ingredient to the question you are investigating instead of assuming that four ingredients must outperform two or three.

KLOW peptide benefits

The useful distinction is the benefit, the ingredient and the route. Wrinkle improvement with a skin serum, knee-pain relief after a joint procedure and intestinal effects after oral KPV are different findings. None establishes that one KLOW injection schedule delivers all three results.

For skin goals, fine lines, scars, hair thinning and loose skin also need separate answers. A change in fine lines does not establish scar removal or hair regrowth. For recovery, less pain does not by itself demonstrate a repaired tendon tear or regenerated cartilage. Read the full skin, gut, joint and tissue-repair benefits article →

KLOW dosage and ingredient amounts

4 mg total KLOW = 2.5 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 + 500 mcg KPV. That is the calculator’s starting example. The target is the whole blend, not 4 mg of GHK-Cu or 500 mcg of the whole blend.

The same 80 mg vial at a final 3 mL volume has a concentration of about 26.67 mg/mL. A 4 mg target then needs 0.15 mL, or 15 U-100 units. More water changes the volume needed for the target; it does not change the ingredient ratio or add peptide.

One documented KLOW schedule used about 4 mg total per day, split between morning and evening, for six weeks. Ipamorelin and retatrutide were also used. It is an individual schedule, not a tested standard for the blend. [9] The dosage article compares that account with another daily amount and explains the concentration math.

“500 mcg KLOW” and “500 mcg BPC-157 within KLOW” are eightfold different totals. The first contains 62.5 mcg BPC-157. The second requires 4,000 mcg of the total blend and also includes the other three ingredients. Enter the intended total in the target-first KLOW calculator; it shows all four amounts alongside the liquid volume and syringe scale.

KLOW cycle length and results

Six weeks is one documented KLOW course. That duration does not establish the best course length or a deadline for visible results. Daily use and five days per week produce different weekly totals. [9] At a 4 mg total amount, seven active days equal 28 mg per week; five active days equal 20 mg. Across six weeks, those schedules represent 168 mg and 120 mg respectively.

These are quantity calculations, not recommended courses. Neither an 80 mg vial nor a 240 mg pen defines the right duration. Remaining liquid is not a reason to extend a course, and the number of mathematical portions does not set the product’s usable life after opening.

KLOW experiences include visible skin changes, pain improvement, no noticeable benefit and fatigue. The before-and-after article gives the actual timelines and accompanying treatments for the individual accounts. It also separates those experiences from studies of single ingredients.

Taking the blend in the morning rather than evening does not establish faster repair. Splitting a daily amount into two administrations changes the schedule without reducing the total. The timing and cycle sections cover these differences, including why weekend breaks and time off between courses answer different questions.

80 mg vial or 240 mg pen

Research-labelled products. Drawings show the formats; they are not product photographs.

The pen contains three times the vial’s total blend amount. Its 3 mL cartridge contains 150 mg GHK-Cu and 30 mg each of BPC-157, TB-500 and KPV. The concentration is fixed at 80 mg/mL. The powder vial’s concentration depends on its final mixed volume. [1]

At a 4 mg arithmetic target, the vial contains 20 portions and the pen contains 60. Those counts exclude losses and discard limits. With the vial mixed to 2 mL, that target occupies 0.1 mL; in the pen it occupies 0.05 mL. Copying the same number from one format to the other can therefore double the amount.

The supplied pen scale is 0.01 mL per marked unit, making 4 mg equal to five marked units at 80 mg/mL. A marked unit is not automatically one audible click. The device’s click calibration must be confirmed before using clicks as a measurement.

Prepared vial solution and the prefilled pen use refrigerated storage at 2–8°C. The sealed powder’s listed storage is −20°C, dry and protected from light. Freezer instructions for powder do not apply to the pen. No universal after-opening expiry is verified in the supplied documents. [1]

Compare both KLOW formats, storage and batch testing →

Stacking KLOW with GLOW, BPC-157 or Wolverine

KLOW already contains BPC-157, TB-500, GHK-Cu and KPV. Adding a second peptide product can duplicate one, two or three ingredients. The combined amount matters even if the products have different names or are used at different times of day.

These examples explain overlap; they do not establish a more effective stack. There is no demonstrated interaction schedule that makes the duplication necessary. If the goal is to change only KPV, a fixed four-ingredient blend cannot make that adjustment independently.

KLOW side effects

No reliable percentage describes how often each reaction occurs with this four-ingredient blend. Adding KPV also adds an ingredient without an established human safety profile; its short amino-acid sequence is not proof of safety. [8]

KLOW safety: symptoms, copper, interactions and groups needing extra caution →

Redacted KLOW batch certificate

Lot PL-2609-057 has a combined HPLC area purity of 99.66%. The redacted in-house report identifies all four ingredients in sampled powder vials. It also lists endotoxin, water-content and sterility results. [2]

The certificate’s purity percentage is not a separate measurement of each ingredient’s milligram fill. It also does not establish that the finished pen solution, cartridge and filling process passed the same tests. The buying article includes the redacted PDF and the exact scope of each result.